Marksans Pharma Limited — PPTs, 12-08-2026: Investor Presentation

Marksans Pharma delivered a stellar Q1FY27. Revenue jumped 35.6% YoY to ₹841 Cr, driven significantly by UK & Europe's 74.7% growth to ₹356 Cr. EBITDA surged 112.8% to ₹213 Cr, pushing margins to 25.3% (+919 bps), while net profit rose 173.9% to ₹159 Cr. Diluted EPS was ₹3.5.

The company is strategically focused on expanding its high-growth OTC business and global footprint, particularly in Europe. Recent wins include acquiring QliniQ B.V. and ABCnow GmbH, establishing a strong front-end presence across new European markets. Marksans also crossed ₹1,000 Cr in cash balance, reaching ₹1,058 Cr.

Management is confident in carrying this momentum forward, scaling operations across geographies, accelerating new product launches from its 200+ product pipeline, and strengthening its European platform for sustainable future growth.